John Timothy Greenamyre

powered by
COS Expertise®
University of Pittsburgh
School of Medicine
Neurology
ProfessorAppointed: 2004
University of Pittsburgh
School of Medicine
Pittsburgh Institute for Neurodegenerative Diseases
DirectorAppointed: 2004
Professional Headshot of John Timothy Greenamyre

Mailing Address

University of Pittsburgh
3501 Fifth Ave., Suite 7039
Pittsburgh, Pennsylvania 15260
United States

Contact Information

Phone: (412) 648-9793
Fax: (412) 648-9766
jgreena@pitt.edu

Qualifications

M.D., University of Michigan, Medicine, 1986.
Ph.D., University of Michigan, Neuroscience, 1986.
B.S., Michigan State University, Microbiology, 1977.

Expertise and Research Interests

Our lab is interested in mechanisms that cause nerve cell death in disorders such as Parkinson's, Huntington's and Alzheimer's diseases. The work focuses on mitochondrial impairment, oxidative damage, protein aggregation, calcium homeostasis and excitotoxicity. The general strategy is to define mechanisms that cause nerve cell death, and then use them as potential ''targets'' for therapeutic intervention. The lab employs in vivo models of neurodegeneration and in vitro culture of cells and brain slices to study mechanisms of degeneration with a variety of biochemical, anatomical, and physiological techniques. A novel model of Parkinson's disease has been developed and is being used to screen potential neuroprotective strategies (Nature Neuroscience 3:1301-1306, 2000). Peripheral cells from patients are also used for physiological studies (Nature Neuroscience 5:731-736, 2002). Another interest of the lab is the role of glutamate neurotransmission in the symptoms of Parkinson's disease.

Other Expertise

Special Reviewer, National Institute of Child Health & Human Development, 1991
Special Reviewer, Neurology A Study Section, NINDS, 1992-1994
Special Reviewer, Program Project Review B Committee, NINDS, 1992-1995
Special Reviewer, Neuroscience, Behaviorand Sociologyof Aging Review Committee, NIA, 1994
Special Reviewer, Neurology C Study Section, NINDS, 1995
Scientific Advisory Board, Dystonia Medical Research Foundation, 1995-1998
Chair, Grants and Fellowships Committee, Huntington's Disease Society of America, 1998-
Member, Medical/Scientific Advisory Committee, Huntington's Disease Society of America, 1998-
Member, Neurological Sciences and Disorders Review Subcommittee B (NSD-B), NINDS, 1997-2001
Member, Parkinson's Disease Research Agenda Planning Committee, NIH, 2000
Member, Parkinson's Disease Research Implemenation Committee, NIH, 2000-
Member, Scientific Advisory Board, Parkinson Study Group, 2000-2004
Steering Committee, Michael J. Fox Foundation, 2000-01
Director's Leadership Retreat, National Institute of Environmental Health Science, 2001
Member, Scientific Advisory Committee, Michael J. Fox Foundation, 2001-
Member, Scientific Committee, Telethon Italy (The 2nd largest charity in Italy - funds scientific research on genetic diseases), 2002-06
Chair, Scientific Advisory Committee, Parkinson's Study Group
Executive Committee, Michael J. Fox Foundation

Editorships and Editorial Boards:
1997-04-Editorial Board, Experimental Neurology
1998-Editorial Board, Neurology
2000-04-Section Editor, Experimental Neurology
2002-Section Editor, Functional Neurology
2003-Associate Editor, Journal of Neuroscience
2003-Editorial Board, Movement Disorders
2005-Editor, Neurobiology of Disease

Keywords

COS Keywords:

Alzheimer's Disease, Anatomy, Animal Models, Apoptosis, Confocal Microscopy, Disease Model, Huntington's Disease, Medical Education, Microbiology, Microscopy, Neuroanatomy, Neurobiology, Neurochemistry, Neurodegenerative Diseases, Neurology, Neuroscience, Parkinson's Disease, Pharmacology.

Additional Terms:

Alzheimer's Disease, Excitatory Amino Acids, Excitotoxicity, Glutamate, Huntington's Disease, Laser Scanning Confocal Microscopy, Mitochondria, Parkinson's Disease.

Memberships

American Academy of Neurology
American Association for the Advancement of Science
American Neurological Association
Huntington's Study Group
International Society for Neurochemistry
Movement Disorders Society
Parkinson's Study Group
Society for Neuroscience

Honors and Awards

2004, UPMC Endowed Professorship in Movement Disorders, University of Pittsburgh Medical Center
2004, Presidential Lecture, Annual Meeting, Society for Neuroscience
2003, Team Hope Award for Medical Leadership, Huntington's Disease Society of America
2003, Nathan L. Cohen Lectureship, Department of Neurology, Johns Hopkins University School of Medicine
2002, John B. Penney Jr. Memorial Lecture, Massachusetts General Hospital, Harvard Medical School
2000, Decade of the Brain Plenary Lecturer, American Academy of Neurology
2000, Ottorino Rossi Award, University of Pavia (Italy)
1994, Listed, Best Doctors in America, Movement Disorders
1994-1997, Mallinckrodt Scholar, Edward Mallinckrodt Jr. Foundation
1986, Medical Scientist Award, University of Michigan

Previous Positions

2003-2004, Vice-chair, Emory University, School of Medicine, Neurology
1998-2004, Professor, Emory University, School of Medicine, Neurology
1995-1997, Associate Professor, Emory University, School of Medicine, Neurology and Pharmacology
1993-1995, Associate Professor, University of Rochester, School of Medicine, Neurology/Pharmacology/Neurobiology and Anatomy
1990-1993, Assistant Professor, University of Rochester, School of Medicine, Neurology/Pharmacology/Neurobiology and Anatomy

Patents

Methods of administering an AMPA receptor antagonist to treat dyskinesias associated with dopamine agonist therapy, Patent Number: pending, 1998, Industry-owned, United States of America.

Funding Received

  • NIEHS (NIH): 1 U54 ES012068: The Emory Collaborative Center for PD Environmental Research, $1,309,000/yr, Sep 1, 2002 to Aug 31, 2007.
  • NINDS (NIH): Training in Translational Research in Neurology, $243,005/yr, Oct 1, 2000 to Sep 30, 2005.
  • The Picower Foundation: Pathogenic Mechanisms as Therapeutic Targets In Parkinson's Disease, $750,000/yr, 2004 to 2007.
  • Huntington's Disease Society of America: Glucose metabolism and mitochondria in HD, $100,000/yr, 2004 to 2006.

Publications

  • Richardson JR, Quan Y, Sherer TB, Greenamyre JT, Miller GW (Nov 2005) Paraquat neurotoxicity is distinct from that of MPTP and rotenone., Toxicological Sciences : an Official Journal of the Society of Toxicology, 88 (1), 193-201 Abstract
  • Puri BK, Leavitt BR, Hayden MR, Ross CA, Rosenblatt A, Greenamyre JT, Hersch S, Vaddadi KS, Sword A, Horrobin DF, Manku M, Murck H (Jul 2005) Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial., Neurology, 65 (2), 286-92 Abstract
  • Testa CM, Sherer TB, Greenamyre JT (Mar 2005) Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures., Brain Research. Molecular Brain Research, 134 (1), 109-18 Abstract
  • Betarbet R, Sherer TB, Greenamyre JT (Feb 2005) Ubiquitin-proteasome system and Parkinson's diseases., Experimental Neurology, 191 Suppl 1, S17-27 Abstract
  • Greene JG, Dingledine R, Greenamyre JT (Feb 2005) Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism., Neurobiology of Disease, 18 (1), 19-31 Abstract
  • Panov AV, Lund S, Greenamyre JT (Jan 2005) Ca2+-induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington's disease individuals., Molecular and Cellular Biochemistry, 269 (1-2), 143-52 Abstract
  • Sherer TB, Greenamyre JT (May-Jun 2005) Oxidative damage in Parkinson's disease., Antioxidants & Redox Signaling, 7 (5-6), 627-9 Abstract
  • Sherer TB, Greenamyre JT (May-Jun 2005) Oxidative damage in Parkinson's disease., Antioxidants & Redox Signaling, 7 (5-6), 627-9 Abstract
  • Papa SM, Auberson YP, Greenamyre JT, Prolongation of levodopa responses by glycineB antagonists in parkinsonian primates, Annals of Neurology, 56(5), 723-7, Nov 2004 Abstract
  • Betarbet R, Greenamyre JT, Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP, Experimental Neurology, 189(2), 393-403, Oct 2004 Abstract
  • Soares J, Kliem MA, Betarbet R, Greenamyre JT, Yamamoto B, Wichmann T, Role of external pallidal segment in primate parkinsonism: comparison of the effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism and lesions of the external pallid, The Journal of Neuroscience : the Official Journal of the Society for Neuroscience., 24(29), 6417-26, Jul 2004 Abstract
  • Betarbet R, Poisik O, Sherer TB, Greenamyre JT, Differential expression and ser897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 in animal models of Parkinson's disease, Experimental Neurology, 187(1), 76-85, 2004 Abstract
  • Greenamyre JT, Hastings TG, Biomedicine. Parkinson's--divergent causes, convergent mechanisms, Science, 304(5674), 1120-2, 2004 Abstract
  • Panov AV, Andreeva L, Greenamyre JT, Quantitative evaluation of the effects of mitochondrial permeability transition pore modifiers on accumulation of calcium phosphate: comparison of rat liver and brain mitochondria, Archives of Biochemistry and Biophysics, 424(1), 44-52, 2004 Abstract
  • Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT, Mechanism of toxicity in rotenone models of Parkinson's disease, The Journal of Neuroscience : the Official Journal of the Society for Neuroscience., 23(34), 10756-64, 2003 Abstract
  • Greenamyre JT, Betarbet R, Sherer TB, The rotenone model of Parkinson's disease: genes, environment and mitochondria, Parkinsonism & Related Disorders, 9 Suppl 2, S59-64, 2003 Abstract
  • Sherer TB, Betarbet R, Kim JH, Greenamyre JT, Selective microglial activation in the rat rotenone model of Parkinson's disease, Neuroscience Letters, 341(2), 87-90, 2003 Abstract
  • Panov AV, Burke JR, Strittmatter WJ, Greenamyre JT, In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease, Archives of Biochemistry and Biophysics, 410(1), 1-6, February 2003 Abstract
  • Sherer TB, Kim JH, Betarbet R, Greenamyre JT, Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation, Experimental Neurology, 179(1), 9-16, 2003 Abstract
  • Betarbet R, Sherer TB, Di Monte DA, Greenamyre JT, Mechanistic approaches to Parkinson's disease pathogenesis, Brain Pathology (zurich, Switzerland), 12(4), 499-510, October 2002 Abstract
  • Stephans SE, Miller GW, Levey AI, Greenamyre JT, Acute mitochondrial and chronic toxicological effects of 1-methyl-4-phenylpyridinium in human neuroblastoma cells, Neurotoxicology, 23(4-5), 569-80, October 2002 Abstract
  • Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT, Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines, Nature Neuroscience, 5(8), 731-6, Aug 2002 Abstract
  • Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT, An In Vitro Model of Parkinson's Disease: Linking Mitochondrial Impairment to Altered alpha -Synuclein Metabolism and Oxidative Damage, Journal of Neuroscience, 22(16), 7006-15, Aug 2002
  • Sherer TB, Betarbet R, Greenamyre JT, Environment, mitochondria, and Parkinson's disease, The Neuroscientist, 8(3), 192-7, June 2002
  • Betarbet R, Sherer TB, Greenamyre JT, Animal models of Parkinson's disease, Bioessays, 24(4), 308-18, April 2002
  • Greenamyre JT, Shoulson I, We need something better, and we need it now: fetal striatal transplantation in Huntington's disease?, Neurology, 58(5), 675-6, March 2002 Abstract
  • Sherer TB, Betarbet R, Greenamyre JT, Pathogenesis of Parkinson's disease, Current Opinion in Investigational Drugs, 2(5), 657-62, May 2001
  • Blandini F, Nappi G, Greenamyre JT, Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease, Annals of Neurology, 49(4), 525-9, April 2001 Abstract
  • Greenamyre JT, Glutamatergic influences on the basal ganglia, Clinical Neuropharmacology, 24(2), 65-70, 2001 Abstract
  • Blandini F, Greenamyre JT, Fancellu R, Nappi G, Blockade of subthalamic glutamatergic activity corrects changes in neuronal metabolism and motor behavior in rats with nigrostriatal lesions, Neurological Sciences, 22(1), 49-50, February 2001
  • Shoulson I, Penney J, McDermott M, Schwid S, Kayson E, Chase T, Fahn S, Greenamyre JT, et al., A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease, Neurology, 56(4), 455-62, 2001 Abstract
  • Simon DK, Tarnopolsky MA, Greenamyre JT, Johns DR, A frameshift mitochondrial complex I gene mutation in a patient with dystonia and cataracts: is the mutation pathogenic?, Journal of Medical Genetics, 38(1), 58-61, Jan 2001
  • Greenamyre JT, Sherer TB, Betarbet R, Panov AV, Complex I and Parkinson's disease, IUBMB Life, 52(3-5), 135-41, 2001
  • Sherer T, Greenamyre JT, A therapeutic target and biomarker in Friedreich's ataxia, Neurology, 55(11), 1600-1, 2000 Abstract
  • Talpade DJ, Greene JG, Higgins DS, Greenamyre JT, In vivo labeling of mitochondrial complex I (NADH:ubiquinone oxidoreductase) in rat brain using [(3)H]dihydrorotenone, Journal of Neurochemistry, 75(6), 2611-21, December 2000 Abstract
  • Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT, Chronic systemic pesticide exposure reproduces features of Parkinson's disease, Nature Neuroscience, 3(12), 1301-6, December 2000 Abstract
  • Jha N, Jurma O, Lalli G, Liu Y, Pettus EH, Greenamyre JT, Liu RM, Forman HJ, Andersen JK, Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease, Journal of Biological Chemistry, 275(34), 26096-101, August 2000 Abstract
  • Pettus EH, Betarbet R, Cottrell B, Wallace DC, Madyastha V, Greenamyre JT, Immunocytochemical characterization of the mitochondrially encoded ND1 subunit of complex I (NADH : ubiquinone oxidoreductase) in rat brain, Journal of Neurochemistry, 75(1), 383-92, July 2000 Abstract
  • Steece-Collier K, Chambers LK, Jaw-Tsai SS, Menniti FS, Greenamyre JT, Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors, Experimental Neurology, 163(1), 239-43, May 2000 Abstract
  • A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for PD. Parkinson Study Group, Neurology, 54(8), 1583-8, April 2000 Abstract
  • Greenamyre JT, 'Ottorino Rossi' Award 2000. New targets for therapy in Parkinson's disease: pathogenesis and pathophysiology, Functional Neurology, 15(2), 67-80, 2000 Abstract
  • Betarbet R, Porter RH, Greenamyre JT, GluR1 glutamate receptor subunit is regulated differentially in the primate basal ganglia following nigrostriatal dopamine denervation., Journal of Neurochemistry, 74(3), 1166-74, 2000 Abstract
  • Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, Orme C, Paulsen J, Penney JB Jr, Siemers E, Shoulson I, Rate of functional decline in Huntington's disease. Huntington Study Group, Neurology, 54(2), 452-8, Jan 2000 Abstract
  • Betarbet R, Greenamyre JT, Differential expression of glutamate receptors by the dopaminergic neurons of the primate striatum, Experimental Neurology, 159(2), 401-8, October 1999 Abstract
  • Sawa A, Wiegand GW, Cooper J, Margolis RL, Sharp AH, Lawler JF Jr, Greenamyre JT, Snyder SH, Ross CA, Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization, Nature Medicine, 5(10), 1194-8, October 1999 Abstract
  • The impact of remacemide hydrochloride on levodopa concentrations in Parkinson's disease. Parkinson Study Group, Clinical Neuropharmacology, 22(4), 220-5, 1999 Abstract
  • Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group [see comments], New England Journal of Medicine, 340(10), 757-63, March 1999 Abstract
  • Panov A, Obertone T, Bennett-Desmelik J, Greenamyre JT, Ca(2 )-dependent permeability transition and complex I activity in lymphoblast mitochondria from normal individuals and patients with Huntington's or Alzheimer's disease, Annals of the New York Academy of Sciences, 893, 365-8, 1999 Abstract
  • Panov A, Obertone T, Bennett-Desmelik J, Greenamyre JT, Ca\(2+\)-dependent permeability transition and complex I activity in lymphoblast mitochondria from normal individuals and patients with Huntington''s or Alzheimer''s disease., Annals of the New York Academy of Sciences, 893, 365-8, 1999 Abstract
  • Peng T I, Greenamyre J T, Privileged access to mitochondria of calcium influx through N-methyl-D-aspartate receptors., Molecular Pharmacology, 53(6), 974-80, June 1998 Abstract
  • Greene J G, Sheu S S, Gross R A, Greenamyre J T, 3-Nitropropionic acid exacerbates N-methyl-D-aspartate toxicity in striatal culture by multiple mechanisms., Neuroscience, 84(2), 503-10, May 1998 Abstract
  • Blandini F, Greenamyre J T, Prospects of glutamate antagonists in the therapy of Parkinson's disease., Fundamental and Clinical Pharmacology, 12(1), 4-12, 1998 Abstract
  • Blandini F, Nappi G, Greenamyre J T, Quantitative study of mitochondrial complex I in platelets of parkinsonian patients., Movement Disorders, 13(1), 11-5, Jan 1998 Abstract
  • Peng TI, Jou MJ, Sheu SS, Greenamyre JT, Visualization of NMDA receptor-induced mitochondrial calcium accumulation in striatal neurons, Experimental Neurology, 149(1), 1-12, Jan 1998 Abstract
  • Cory-Slechta D A, Flaugher C L, Evans S B, Pokora M J, Greenamyre J T, Susceptibility of adult rats to lead-induced changes in NMDA receptor complex function., Neurotoxicology and Teratology, 19(6), 517-30, November 1997 Abstract
  • Betarbet R, Turner R, Chockkan V, DeLong MR, Allers KA, Walters J, Levey AI, Greenamyre JT, Dopaminergic neurons intrinsic to the primate striatum, Journal of Neuroscience, 17(17), 6761-8, September 1997 Abstract
  • Blandini F, Garcia-Osuna M, Greenamyre J T, Subthalamic ablation reverses changes in basal ganglia oxidative metabolism and motor response to apomorphine induced by nigrostriatal lesion in rats., European Journal of Neuroscience, 9(7), 1407-13, July 1997 Abstract
  • Cory-Slechta D A, Garcia-Osuna M, Greenamyre J T, Lead-induced changes in NMDA receptor complex binding: correlations with learning accuracy and with sensitivity to learning impairments caused by MK-801 and NMDA administration., Behavioural Brain Research, 85(2), 161-74, May 1997 Abstract
  • Kilbourn M R, Charalambous A, Frey K A, Sherman P, Higgins D S Jr, Greenamyre J T, Intrastriatal neurotoxin injections reduce in vitro and in vivo binding of radiolabeled rotenoids to mitochondrial complex I., Journal of Cerebral Blood Flow and Metabolism, 17(3), 265-72, March 1997 Abstract
  • Higgins D S Jr, Greenamyre J T, [3H]dihydrorotenone binding to NADH: ubiquinone reductase (complex I) of the electron transport chain: an autoradiographic study., Journal of Neuroscience, 16(12), 3807-16, 15 Jun 1996 Abstract
  • Kieburtz K, Feigin A, McDermott M, Como P, Abwender D, Zimmerman C, Hickey C, Orme C, Claude K, Sotack J, Greenamyre J T, Dunn C, Shoulson I, A controlled trial of remacemide hydrochloride in Huntington's disease., Movement Disorders, 11(3), 273-7, May 1996 Abstract
  • Greenamyre J T, Pharmacological pallidotomy with glutamate antagonists, Annals of Neurology, 39(5), 557-8, May 1996 Abstract
  • Greene J G, Greenamyre J T, Bioenergetics and glutamate excitotoxicity., Progress In Neurobiology, 48(6), 613-34, April 1996 Abstract
  • Blandini F, Porter R H, Greenamyre J T, Glutamate and Parkinson's disease., Molecular Neurobiology, 12(1), 73-94, February 1996 Abstract
  • Greene J G, Greenamyre J T, Manipulation of membrane potential modulates malonate-induced striatal excitotoxicity in vivo., Journal of Neurochemistry, 66(2), 637-43, February 1996 Abstract
  • Blandini F, Greenamyre J T, Nappi G, The role of glutamate in the pathophysiology of Parkinson's disease., Functional Neurology, 11(1), 3-15, January 1996 Abstract
  • Greene J G, Porter R H, Greenamyre J T, ARL-15896, a novel N-methyl-D-aspartate receptor ion channel antagonist: neuroprotection against mitochondrial metabolic toxicity and regional pharmacology., Experimental Neurology, 137(1), 66-72, January 1996 Abstract
  • Blandini F, Greenamyre J T, Assay of [3H]dihydrorotenone binding to complex I in intact human platelets., Analytical Biochemistry, 230(1), 16-9, 1 Sep 1995 Abstract
  • Angel R, Greenamyre J T, Chronic treatment with thioctic acid does not protect against malonate toxicity in vivo., Neuroscience Letters, 196(1-2), 125-7, 18 Aug 1995 Abstract
  • Messam C A, Greene J G, Greenamyre J T, Robinson M B, Intrastriatal injections of the succinate dehydrogenase inhibitor, malonate, cause a rise in extracellular amino acids that is blocked by MK-801., Brain Research, 684(2), 221-4, 3 Jul 1995 Abstract
  • Davolio C, Greenamyre J T, Selective vulnerability of the CA1 region of hippocampus to the indirect excitotoxic effects of malonic acid., Neuroscience Letters, 192(1), 29-32, 2 Jun 1995 Abstract
  • Greene J G, Greenamyre J T, Exacerbation of NMDA, AMPA, and L-glutamate excitotoxicity by the succinate dehydrogenase inhibitor malonate., Journal of Neurochemistry, 64(5), 2332-8, May 1995 Abstract
  • Blandini F, Porter R H, Greenamyre J T, Autoradiographic study of mitochondrial complex I and glutamate receptors in the basal ganglia of rats after unilateral subthalamic lesion., Neuroscience Letters, 186(2-3), 99-102, 17 Feb 1995 Abstract
  • Porter R H, Greenamyre J T, Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential., Journal of Neurochemistry, 64(2), 614-23, February 1995 Abstract
  • Blandini F, Greenamyre J T, Effect of subthalamic nucleus lesion on mitochondrial enzyme activity in rat basal ganglia., Brain Research, 669(1), 59-66, 9 Jan 1995 Abstract
  • Greene J G, Greenamyre J T, Characterization of the excitotoxic potential of the reversible succinate dehydrogenase inhibitor malonate., Journal of Neurochemistry, 64(1), 430-6, January 1995 Abstract
  • Porter R H, Greenamyre J T, Regional variations in the pharmacology of AMPA receptors as revealed by receptor autoradiography., Brain Research, 664(1-2), 202-6, 21 Nov 1994 Abstract
  • Greenamyre J T, Porter R H, Anatomy and physiology of glutamate in the CNS., Neurology, 44(11 Suppl 8), S7-13, November 1994 Abstract
  • Porter R H, Greene J G, Higgins D S Jr, Greenamyre J T, Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activities in the basal ganglia of rats with unilateral dopamine depletion., Journal of Neuroscience, 14(11 Pt 2), 7192-9, November 1994 Abstract
  • Greenamyre J T, Eller R V, Zhang Z, Ovadia A, Kurlan R, Gash D M, Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease [comment], Annals of Neurology, 35(6), 655-61, June 1994 Abstract
  • Greenamyre J T, Garcia-Osuna M, Greene J G, The endogenous cofactors, thioctic acid and dihydrolipoic acid, are neuroprotective against NMDA and malonic acid lesions of striatum., Neuroscience Letters, 171(1-2), 17-20, 25 Apr 1994 Abstract
  • Porter R H, Greenamyre J T, Inhibition of autoradiographic MK-801 binding by an endogenous factor., Neuroscience Letters, 169(1-2), 105-8, 14 Mar 1994 Abstract
  • Sandhu F A, Porter R H, Eller R V, Zain S B, Salim M, Greenamyre J T, NMDA and AMPA receptors in transgenic mice expressing human beta-amyloid protein., Journal of Neurochemistry, 61(6), 2286-9, December 1993 Abstract
  • Greene J G, Porter R H, Eller R V, Greenamyre J T, Inhibition of succinate dehydrogenase by malonic acid produces an "excitotoxic" lesion in rat striatum., Journal of Neurochemistry, 61(3), 1151-4, September 1993 Abstract
  • Greenamyre J T, Maragos W F, Neurotransmitter receptors in Alzheimer disease., Cerebrovascular and Brain Metabolism Reviews, 5(2), 61-94, 1 Jul 1993 Abstract
  • Greenamyre J T, Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease., Journal of Neural transmission. General Section, 91(2-3), 255-69, 1993 Abstract
  • Greenamyre J T, Higgins D S, Eller R V, Quantitative autoradiography of dihydrorotenone binding to complex I of the electron transport chain., Journal of Neurochemistry, 59(2), 746-9, August 1992 Abstract
  • Albin R L, Greenamyre J T, Alternative excitotoxic hypotheses., Neurology, 42(4), 733-8, April 1992 Abstract
  • Kieburtz K D, Epstein L G, Gelbard H A, Greenamyre J T, Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex. Therapeutic implications., Archives of Neurology, 48(12), 1281-4, December 1991 Abstract
  • Klockgether T, Turski L, Honore T, Zhang Z M, Gash D M, Kurlan R, Greenamyre J T, The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys., Annals of Neurology, 30(5), 717-23, November 1991 Abstract
  • Greenamyre J T, O'Brien C F, N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease, Archives of Neurology, 48(9), 977-81, September 1991 Abstract
  • Greenamyre J T, Neuronal bioenergetic defects, excitotoxicity and Alzheimer's disease: "use it and lose it" [comment], Neurobiology of Aging, 12(4), 334-6; discussion 35, July 1991 Abstract
  • Maragos W F, Greenamyre J T, Chu D C, Penney J B, Young A B, A study of cortical and hippocampal NMDA and PCP receptors following selective cortical and subcortical lesions., Brain Research, 538(1), 36-45, 4 Jan 1991 Abstract
  • Penney J B, Maragos W F, Greenamyre J T, Debowey D L, Hollingsworth Z, Young A B, Excitatory amino acid binding sites in the hippocampal region of Alzheimer's disease and other dementias., Journal of Neurology, Neurosurgery and Psychiatry, 53(4), 314-20, April 1990 Abstract
  • Greenamyre J T, Higgins D S, Young A B, Sodium-dependent D-aspartate 'binding' is not a measure of presynaptic neuronal uptake sites in an autoradiographic assay., Brain Research, 511(2), 310-8, 19 Mar 1990 Abstract
  • Greenamyre J T, Higgins D S, Young A B, Penney J B, Regional ontogeny of a unique glutamate recognition site in rat brain: an autoradiographic study., International Journal of Developmental Neuroscience, 8(4), 437-45, 1990 Abstract
  • Greenamyre J T, Young A B, Excitatory amino acids and Alzheimer's disease., Neurobiology of Aging, 10(5), 593-602, September 1989 Abstract
  • Greenamyre J T, Young A B, Synaptic localization of striatal NMDA, quisqualate and kainate receptors., Neuroscience Letters, 101(2), 133-7, 19 Jun 1989 Abstract
  • Cha J H, Hollingsworth Z R, Greenamyre J T, Young A B, Contamination of commercially available quisqualic acid by glutamate-like and aspartate-like substances., Journal of Neuroscience Methods, 27(2), 143-8, March 1989 Abstract

Profile Details

Last Verified: 9/26/2006

COS Expertise ID #407081
Reference this profile directly: http://myprofile.cos.com/jgreena